title: Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy.
abstract: BACKGROUND
  Oxandrolone, an anabolic agent, has been administered for 1 year post burn with beneficial effects in pediatric patients. However, the long-lasting effects of this treatment have not been studied. This single-center prospective trial determined the long-term effects of 1 year of oxandrolone administration in severely burned children; assessments were continued for up to 4 years post therapy.
  
  
  METHODS
  Patients 0 to 18 years old with burns covering >30% of the total body surface area were randomized to receive placebo (n = 152) or oxandrolone, 0.1 mg/kg twice daily for 12 months (n = 70). At hospital discharge, patients were randomized to a 12-week exercise program or to standard of care. Resting energy expenditure, standing height, weight, lean body mass, muscle strength, bone mineral content (BMC), cardiac work, rate pressure product, sexual maturation, and concentrations of serum inflammatory cytokines, hormones, and liver enzymes were monitored.
  
  
  RESULTS
  Oxandrolone substantially decreased resting energy expenditure and rate pressure product, increased insulin-like growth factor-1 secretion during the first year after burn injury, and, in combination with exercise, increased lean body mass and muscle strength considerably. Oxandrolone-treated children exhibited improved height percentile and BMC content compared with controls. The maximal effect of oxandrolone was found in children aged 7 to 18 years. No deleterious side effects were attributed to long-term administration.
  
  
  CONCLUSIONS
  Administration of oxandrolone improves long-term recovery of severely burned children in height, BMC, cardiac work, and muscle strength; the increase in BMC is likely to occur by means of insulin-like growth factor-1. These benefits persist for up to 5 years post burn.
authors.affiliation: Shriners Hospitals for Children-Galveston, Galveston, TX 77550, USA.
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Porro
authors.forename: David N
authors.initials: DN
authors.lastname: Herndon
authors.forename: Noe A
authors.initials: NA
authors.lastname: Rodriguez
authors.forename: Kristofer
authors.initials: K
authors.lastname: Jennings
authors.forename: Gordon L
authors.initials: GL
authors.lastname: Klein
authors.forename: Ronald P
authors.initials: RP
authors.lastname: Mlcak
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Meyer
authors.forename: Jong O
authors.initials: JO
authors.lastname: Lee
authors.forename: Oscar E
authors.initials: OE
authors.lastname: Suman
authors.forename: Celeste C
authors.initials: CC
authors.lastname: Finnerty
mesh_terms: D000293:Adolescent; D045930:Anabolic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D049628:Body Size / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D002056:Burns / Q000188:drug therapy* / Q000378:metabolism / Q000534:rehabilitation; D002153:Calorimetry, Indirect; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004734:Energy Metabolism / Q000187:drug effects; D005081:Exercise Therapy; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008099:Liver / Q000187:drug effects; D008297:Male; D053580:Muscle Strength / Q000187:drug effects; D010074:Oxandrolone / Q000494:pharmacology / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D045930:Anabolic Agents; D015415:Biomarkers; D007334:Insulin-Like Growth Factor I; D010074:Oxandrolone